Mannatech, Incorporated is a small wellness company that develops and sells nutritional supplements, skin-care and anti-aging products, and weight-management items, primarily through network marketing and e-commerce channels. It is a Nasdaq-listed stock, not an exchange-traded fund, with a market capitalization of only about $16.5 million.
Because credible Wall Street coverage of MTEX is extremely thin, a conventional analyst-consensus target cannot be reliably calculated. MarketBeat lists no consensus price target, and the individual figures that do circulate are mostly below the market: a $6.00 estimate noted by TipRanks and a $7.50 Hold figure referenced in financial media, alongside a "Sell" rating from Weiss Ratings in October 2026. None of these can support a forward-looking target above the current price.
Accordingly, the $10 level used here is a fallback objective rooted in public discussion and technical structure, not an analyst average. It corresponds closely to the stock's 52-week high — around $9.97 — and to the round-number, psychological $10 mark that market commentary has referenced as a plausible upside milestone if positive catalysts materialize.
With the shares recently trading near $8.56, a move to $10 implies roughly 16.8% upside — a substantial, though not extreme, move. The path would most likely run through a recovery in revenue and profitability, a successful resolution of the going-concern review, or a corporate action such as another tender offer, which has periodically concentrated buying interest in this illiquid stock.
The backdrop is challenging. Revenue has declined from about $137 million in 2022 to roughly $108 million in 2025, and the company posted a net loss with negative earnings per share (EPS) near -$3.91 over the trailing twelve months. A 2026 delay in the annual Form 10-K filing, tied to an auditor's going-concern review, underscores the balance-sheet uncertainty investors must weigh against the stock's low valuation.
The most relevant technical reference point is the 52-week high near $9.97, which sits just below the $10 psychological level and represents a key resistance zone. A decisive move above that area would require sustained buying in a stock with very limited liquidity. On the downside, the prior trading range between roughly $4 and $6.50, seen earlier in the period, marks the main support region below the current price.
Because there is no meaningful analyst consensus, no standardized research horizon applies to the $10 objective. The most important items to watch are the company's quarterly revenue and EPS trends, any update on the going-concern review and cost-reduction plan, and announcements around the annual meeting window, where tender offers have historically been considered. Investors should also monitor whether any new analyst coverage or ratings emerge, given how little independent research currently exists.
For traders looking to track changing conditions in stocks and ETFs, Tickeron's AI Daily Buy/Sell Signals provide a data-driven complement to fundamental research. The system uses artificial intelligence to continuously monitor thousands of securities and generate Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. This can help traders discover new opportunities, keep an eye on existing positions, and identify shifting trends more efficiently than manual scanning alone. For a low-coverage name like MTEX, such tools can offer an additional, objective lens on momentum and risk.
Whether Mannatech can reach $10 depends less on analyst conviction — which is essentially absent — and more on company-specific catalysts such as stabilizing revenue, resolving the going-concern review, or another tender offer. The roughly 16.8% move required is substantial, and the stock's very low valuation and recovery off its low are offset by declining sales, ongoing losses, and balance-sheet uncertainty. With no reliable analyst consensus to lean on, the $10 level should be read as a technical and psychological milestone from public discussion rather than a forecast, and investors should monitor fundamentals closely before drawing any conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that MTEX and COTY have been poorly correlated (+11% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MTEX and COTY's prices will move in lockstep.
| Ticker / NAME | Correlation To MTEX | 1D Price Change % | ||
|---|---|---|---|---|
| MTEX | 100% | -29.84% | ||
| COTY - MTEX | 11% Poorly correlated | +0.25% | ||
| PG - MTEX | 11% Poorly correlated | +1.05% | ||
| UL - MTEX | 9% Poorly correlated | +1.06% | ||
| EL - MTEX | 7% Poorly correlated | +1.12% | ||
| EPC - MTEX | 6% Poorly correlated | -5.08% | ||
More | ||||